Table 1 Correlation between miR-29c expression and different clinical characteristics
From: MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma
| Â | Patients with low miR-29c expression | Patients with high miR-29c expression | p |
|---|---|---|---|
Age | Â | Â | 0.165 |
  < 60 y | 27 (61.4%) | 20 (46.5%) |  |
  ≥ 60 y | 17 (38.6%) | 23 (53.3%) |  |
Sex | Â | Â | 0.458 |
 Male | 27 (61.4%) | 23 (53.5%) |  |
 Female | 17 (38.6%) | 20 (46.5%) |  |
ECOG performance status | Â | Â | 0.740 |
 0 | 21 (47.7%) | 19 (44.2%) |  |
 1 | 23 (52.3%) | 24 (55.8%) |  |
Weight loss | Â | Â | 1.000 |
  ≤ 5% | 42 (95.5%) | 41 (95.3%) |  |
  > 5% | 2 (4.5%) | 2 (4.7%) |  |
Smoking status | Â | Â | 0.137 |
 Smokers | 19 (43.2%) | 12 (27.9%) |  |
 Nonsmokers | 25 (56.8%) | 31 (72.1%) |  |
Tumor stage | Â | Â | 0.324 |
 1 | 3 (6.8%) | 7 (16.3%) |  |
 2 | 32 (72.7%) | 30 (69.8%) |  |
 3 | 9 (20.5%) | 6 (14.0%) |  |
Postoperative chemotherapy | Â | Â | 0.313 |
 Yes | 40 (90.9%) | 36 (83.7%) |  |
 No | 4 (9.1%) | 7 (16.3%) |  |
Postoperative radiotherapy | Â | Â | 0.125 |
 Yes | 12 (27.3%) | 6 (14.0%) |  |
 No | 32 (72.7%) | 37 (86.0%) |  |